Pds Biotechnology (PDSB)
NASDAQ:PDSB
Want to see PDSB full AI Analyst Report?
Top Page
PDS Biotechnology
(NASDAQ:PDSB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$1.00
▼(-23.66% Downside)
Action:Reiterated
Date:06/03/26
The score is held down primarily by very weak financial performance (pre-revenue, sustained losses, cash burn, and balance-sheet risk). Offsetting this, the latest earnings call and recent updates point to meaningful clinical/protocol progress and improved expense trends, while technicals are neutral and valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Strong IP and unique product profile
PDS0101's differentiated dosing/formulation (subcutaneous, five doses) and newly granted U.S. and Japanese patents extending protection into the 2040s create durable product-market exclusivity. This structural advantage supports longer-term commercialization potential and partner interest if clinical endpoints are met.
Negative Factors
No revenue; persistent losses
The company remains pre‑commercial with no material product revenue and consistent operating and free cash flow outflows. Over the medium term this means continued reliance on external capital to fund operations, constraining strategic flexibility and increasing execution risk if funding conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong IP and unique product profile
PDS0101's differentiated dosing/formulation (subcutaneous, five doses) and newly granted U.S. and Japanese patents extending protection into the 2040s create durable product-market exclusivity. This structural advantage supports longer-term commercialization potential and partner interest if clinical endpoints are met.
Read all positive factors
PDS Biotechnology (PDSB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.75M
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)2.96
Revenue GrowthN/A
EPS Growth28.53%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding55,815,655
10 Day Avg. Volume1,189,887
30 Day Avg. Volume1,052,301
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$7.50Price Target Upside472.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
PDS Biotechnology Business Overview & Revenue Model
Company Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treat...
How the Company Makes Money
PDS Biotechnology does not generate meaningful recurring revenue from commercial product sales because its lead programs are in clinical development and, to the extent publicly disclosed, it has not reported ongoing product commercialization. Its ...
PDS Biotechnology Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.Positive Updates
Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
Negative Updates
Cash balance and potential runway considerations
Cash on hand was $21.7M as of March 31, 2026; management did not provide explicit runway or guidance on financing needs, which could raise near-term funding questions given ongoing late-stage and development activities.
Read all updates
Q1-2026 Updates
Positive
Negative
Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
Read all positive updates
Company Guidance
Management guided that the VERSATILE‑003 amendment adopts progression‑free survival as an interim co‑primary endpoint (retaining overall survival for full approval) to enable a potential accelerated approval, changes randomization from 2:1 to 1:1 and reduces planned enrollment from ~350 to ~250 patients to shorten duration, lower external and internal costs and speed an interim readout (sites remained engaged and enrollment is restarting); they reiterated PDS0101’s differentiators (only late‑stage HPV16 HNSCC regimen that is subcutaneous and requires just five doses) and noted new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Financial metrics include cash of $21.7M as of March 31, 2026, a Q1 net loss of ~$7.3M ($0.13 per share) versus $8.5M ($0.21) year‑ago, R&D of $3.5M (vs $5.8M), G&A of $3.1M (vs $3.3M), total operating expenses of $6.5M (vs $9.1M) and net interest expense of $0.8M (vs $0.6M); operational guidance also highlighted an established Versamune manufacturing process with CMC validation/scale‑up ahead of a BLA and that PDS01ADC data (JCO Oncology Advances, NCI/AACR) support advancement—colorectal Stage 2 is fully enrolled with additional data expected by year‑end.PDS Biotechnology Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -59.79K | -57.33K | 0.00 | 0.00 |
| EBITDA | -28.10M | -30.30M | -33.75M | -40.09M | -40.74M | -21.43M |
| Net Income | -33.36M | -34.50M | -37.61M | -42.94M | -40.85M | -16.92M |
Balance Sheet | ||||||
| Total Assets | 24.66M | 30.49M | 45.36M | 59.39M | 77.01M | 67.20M |
| Cash, Cash Equivalents and Short-Term Investments | 21.66M | 26.71M | 41.69M | 56.56M | 73.82M | 65.24M |
| Total Debt | 15.86M | 16.93M | 21.83M | 23.85M | 23.47M | 490.35K |
| Total Liabilities | 20.77M | 21.24M | 26.35M | 33.26M | 33.01M | 3.99M |
| Stockholders Equity | 3.89M | 9.25M | 19.00M | 26.13M | 44.00M | 63.21M |
Cash Flow | ||||||
| Free Cash Flow | -4.39B | -27.75B | -35.06M | -33.64M | -25.71M | -12.49M |
| Operating Cash Flow | -4.39B | -27.75B | -35.03M | -33.64M | -25.71M | -12.49M |
| Investing Cash Flow | 0.00 | 0.00 | -29.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -674.37M | 12.77B | 20.19M | 16.38M | 34.29M | 48.89M |
PDS Biotechnology Technical Analysis
Positive
1.31
Price Trends
1.02
Positive
0.89
Positive
0.94
Positive
Market Momentum
0.02
Positive
52.62
Neutral
42.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDSB, the sentiment is Positive. The current price of 1.31 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.02, and above the 200-day MA of 0.94, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 52.62 is Neutral, neither overbought nor oversold. The STOCH value of 42.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PDSB.
PDS Biotechnology Risk Analysis
PDS Biotechnology disclosed 52 risk factors in its most recent earnings report. PDS Biotechnology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PDS Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $42.28M | -2.64 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $64.75M | -1.93 | -346.03% | ― | ― | 28.53% | |
49 Neutral | $30.64M | -0.59 | -503.79% | ― | ― | 82.28% | |
44 Neutral | $12.65M | -0.61 | -526.36% | ― | ― | 16.33% | |
43 Neutral | $19.40M | -0.33 | -309.60% | ― | ― | 65.65% |
* Healthcare Sector Average
PDSB
PDS Biotechnology
1.16
-0.49
-29.70%
TPST
Tempest Therapeutics
1.31
-5.59
-81.01%
LTRN
Lantern Pharma
3.74
0.40
11.98%
CALC
CalciMedica
0.80
-0.92
-53.49%
SNTI
Senti Biosciences
0.98
-2.41
-71.00%
PDS Biotechnology Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed
Positive
Jun 2, 2026
On February 25, 2026, PDS Biotechnology disclosed that it had received a deficiency letter from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting its continued listing on the Nasdaq Ca...
Business Operations and StrategyPrivate Placements and Financing
PDS Biotechnology Refinances Debt with New Note, Warrant
Positive
May 1, 2026
On April 30, 2026, PDS Biotechnology entered into a securities purchase agreement with YA II PN, LTD. under which it will issue a $6 million promissory note, sold at a discount, and a warrant for up to 2,158,274 common shares at $1.1824 per share,...
Business Operations and StrategyProduct-Related Announcements
PDS Biotechnology Highlights Progress in Versamune Oncology Pipeline
Positive
Apr 24, 2026
On April 24, 2026, PDS Biotechnology updated its corporate presentation, highlighting the advancement of its Versamune-based oncology pipeline led by PDS0101 for HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. The com...
Business Operations and StrategyProduct-Related Announcements
PDS Biotech Reports Promising Interim Data in Colorectal Cancer
Positive
Apr 15, 2026
On April 15, 2026, PDS Biotechnology announced that interim data from Stage 1 of a National Cancer Institute-led Phase 2 trial of its tumor-targeted IL-12 immunocytokine PDS01ADC in metastatic colorectal cancer were published in the March 10, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.